Patents by Inventor Eleanor CLANCY-THOMPSON

Eleanor CLANCY-THOMPSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific PD-1 and TIGIT binding proteins and uses thereof
    Patent number: 11939382
    Abstract: The disclosure relates to binding proteins, including antibodies, that bind to Programmed Death-1 (“PD-1”) and T cell immunoreceptor with Ig and ITIM domains (“TIGIT”). The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: March 26, 2024
    Assignee: MedImmune, LLC
    Inventors: Yariv Mazor, Yue Wang, Gordon Moody, Deepali Malhotra, Michael Overstreet, Eleanor Clancy-Thompson, Karin Lee, Stacy Pryts, Scott Hammond
  • BISPECIFIC PD-1 AND TIGIT BINDING PROTEINS AND USES THEROF
    Publication number: 20220411509
    Abstract: The disclosure relates to binding proteins, including antibodies, that bind to Programmed Death-1 (“PD-1”) and T cell immunoreceptor with Ig and ITIM domains (“TIGIT”). The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.
    Type: Application
    Filed: April 29, 2022
    Publication date: December 29, 2022
    Applicant: MedImmune, LLC
    Inventors: Yariv MAZOR, Yue WANG, Gordon MOODY, Deepali MALHOTRA, Michael OVERSTREET, Eleanor CLANCY-THOMPSON, Karin LEE, Stacy PRYTS, Scott HAMMOND
  • BISPECIFIC ANTIBODY TARGETING PD-1 AND TIM-3
    Publication number: 20220332818
    Abstract: The present disclosure provides methods of altering engagement between T-cell immunoglobulin and mucin domain containing protein-3 (TIM-3) and phosphatidylserine (PS) in a subject. Also provided are methods of treatment using TIM-3 binding protein wherein the TIM-3 binding domain specifically binds to the C?C? and DE loops of the immunoglobulin variable (IgV) domain of TIM-3.
    Type: Application
    Filed: April 12, 2022
    Publication date: October 20, 2022
    Inventors: Kristen POLLIZZI, Scott A. HAMMOND, Yariv MAZOR, Trinity PERRY, Stacy PRYTS, Ashvin R. JAISWAL, Vaheh OGANSEYAN, Chunning YANG, Raffael KUREK, Natalia CEAICOVSCAIA, Charles FERTE, Eleanor CLANCY-THOMPSON